Equillium (EQ)
(Delayed Data from NSDQ)
$0.67 USD
-0.01 (-2.00%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $0.67 0.00 (-0.01%) 5:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.67 USD
-0.01 (-2.00%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $0.67 0.00 (-0.01%) 5:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Zacks News
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
by Sweta Killa
Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
by Zacks Equity Research
Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.
5 Stocks That More Than Doubled in February
by Sweta Killa
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.60% and 19.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
by Sweta Killa
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
by Zacks Equity Research
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
by Zacks Equity Research
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EQ) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Equillium Gains From Positive Results on Coronavirus Drug
by Zacks Equity Research
Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.
Will Equillium Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Equillium.
Equillium Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Equillium has been struggling lately, but the selling pressure may be coming to an end soon.
Can The Uptrend Continue for Equillium?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Equillium
Equillium Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Equillium.